Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trevi Therapeutics Inc.

www.trevitherapeutics.com

Latest From Trevi Therapeutics Inc.

Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019

With about three IPOs per month compared with a pace of nearly six per month in 2018, drug developers have raised $1.55bn with US offerings this year – though returns have been mixed.

Financing Business Strategies

Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day

Public Company Edition: Turning Point's offering priced at $18 and its stock closed at $28.90. Also, Achaogen's bankruptcy reflects difficult antibacterial market, Ophthotech's name change follows strategy shift, and Gilead lays off 150 sales reps. Plus, cell and gene therapy FOPOs flourish.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Dermatology
  • Hepatic (Liver)
  • Neurology, Nervous System
  • Renal System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Trevi Therapeutics Inc.
  • Senior Management
  • Jennifer L Good, Pres. & CEO
    Christopher J Seiter, CFO
    Thomas Sciascia, MD, CMO
    Helena Brett-Smith, MD, Chief Dev. Officer
    Yann Mazabraud, CCO
  • Contact Info
  • Trevi Therapeutics Inc.
    Phone: (203) 304-2499
    195 Church St.
    14th Fl.
    New Haven, CT 06510
    USA
UsernamePublicRestriction

Register